AstraZeneca boss Sir Pascal Soriot (pictured) is thought to be mulling shifting its listing to New York due to growing frustration about UK rules.Read More
You might also be interested in reading S&P Global backs Kaiko as Series B reaches $110M.
AstraZeneca boss Sir Pascal Soriot (pictured) is thought to be mulling shifting its listing to New York due to growing frustration about UK rules.Read More
You might also be interested in reading S&P Global backs Kaiko as Series B reaches $110M.